• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

VISTA/VSIG3/PSGL-1 轴:免疫效应细胞和浸润性导管乳腺癌细胞之间的串扰。

The VISTA/VSIG3/PSGL-1 axis: crosstalk between immune effector cells and cancer cells in invasive ductal breast carcinoma.

机构信息

Department of Histology and Embryology, Department of Human Morphology and Embryology, Wroclaw Medical University, Chalubinskiego 6a, 50-368, Wroclaw, Poland.

Department of Pathology, Polish Mother's Memorial Hospital Research Institute, 93-338, Lodz, Poland.

出版信息

Cancer Immunol Immunother. 2024 Jun 4;73(8):136. doi: 10.1007/s00262-024-03701-w.

DOI:10.1007/s00262-024-03701-w
PMID:38833004
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11150347/
Abstract

A checkpoint protein called the V-domain Ig suppressor of T cell activation (VISTA) is important for controlling immune responses. Immune cells that interact with VISTA have molecules, or receptors, known as VISTA receptors. Immune system activity can be modified by the interaction between VISTA and its receptors. Since targeting VISTA or its receptors may be beneficial in certain conditions, VISTA has been studied in relation to immunotherapy for cancer and autoimmune illnesses. The purpose of this study was to examine the expression levels and interactions between VISTA and its receptors, VSIG3 and PSGL-1, in breast cancer tissues. IHC analysis revealed higher levels of proteins within the VISTA/VSIG3/PSGL-1 axis in cancer tissues than in the reference samples (mastopathies). VISTA was found in breast cancer cells and intratumoral immune cells, with membranous and cytoplasmic staining patterns. VISTA was also linked with pathological grade and VSIG3 and PSGL-1 levels. Furthermore, we discovered that the knockdown of one axis member boosted the expression of the other partners. This highlights the significance of VISTA/VSIG3/PSGL-1 in tumor stroma and microenvironment remodeling. Our findings indicate the importance of the VISTA/VSIG3/PSGL-1 axis in the molecular biology of cancer cells and the immune microenvironment.

摘要

一种名为 T 细胞活化的 V 结构域免疫球蛋白抑制因子(VISTA)的检查点蛋白对于控制免疫反应很重要。与 VISTA 相互作用的免疫细胞具有称为 VISTA 受体的分子或受体。VISTA 与其受体之间的相互作用可以修饰免疫系统的活性。由于靶向 VISTA 或其受体在某些情况下可能是有益的,因此已经研究了 VISTA 与癌症和自身免疫性疾病的免疫疗法的关系。本研究的目的是检查乳腺癌组织中 VISTA 与其受体 VSIG3 和 PSGL-1 之间的表达水平和相互作用。免疫组化分析显示,癌症组织中 VISTA/VSIG3/PSGL-1 轴内的蛋白水平高于参考样本(乳腺病)。在乳腺癌细胞和肿瘤内免疫细胞中发现了 VISTA,其染色模式为膜和细胞质。VISTA 还与病理分级以及 VSIG3 和 PSGL-1 水平相关。此外,我们发现一个轴成员的敲低会增强其他伙伴的表达。这突显了 VISTA/VSIG3/PSGL-1 在肿瘤基质和微环境重塑中的重要性。我们的研究结果表明 VISTA/VSIG3/PSGL-1 在癌细胞的分子生物学和免疫微环境中具有重要意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7c7/11150347/97b4d927388a/262_2024_3701_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7c7/11150347/4189b437c699/262_2024_3701_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7c7/11150347/a70f08c2c31c/262_2024_3701_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7c7/11150347/f76da310c1b1/262_2024_3701_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7c7/11150347/ff301372192c/262_2024_3701_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7c7/11150347/61c268e39335/262_2024_3701_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7c7/11150347/919c01933a8e/262_2024_3701_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7c7/11150347/97b4d927388a/262_2024_3701_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7c7/11150347/4189b437c699/262_2024_3701_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7c7/11150347/a70f08c2c31c/262_2024_3701_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7c7/11150347/f76da310c1b1/262_2024_3701_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7c7/11150347/ff301372192c/262_2024_3701_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7c7/11150347/61c268e39335/262_2024_3701_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7c7/11150347/919c01933a8e/262_2024_3701_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7c7/11150347/97b4d927388a/262_2024_3701_Fig7_HTML.jpg

相似文献

1
The VISTA/VSIG3/PSGL-1 axis: crosstalk between immune effector cells and cancer cells in invasive ductal breast carcinoma.VISTA/VSIG3/PSGL-1 轴:免疫效应细胞和浸润性导管乳腺癌细胞之间的串扰。
Cancer Immunol Immunother. 2024 Jun 4;73(8):136. doi: 10.1007/s00262-024-03701-w.
2
The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer.免疫检查点调节剂 VISTA 在人乳腺癌中的表达模式及临床意义。
Front Immunol. 2020 Oct 29;11:563044. doi: 10.3389/fimmu.2020.563044. eCollection 2020.
3
VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy.VISTA:静止的调解者和癌症免疫治疗的有前途的靶点。
Trends Immunol. 2021 Mar;42(3):209-227. doi: 10.1016/j.it.2020.12.008. Epub 2021 Jan 23.
4
Structural Basis of VSIG3: The Ligand for VISTA.VSIG3 的结构基础:VISTA 的配体。
Front Immunol. 2021 Mar 25;12:625808. doi: 10.3389/fimmu.2021.625808. eCollection 2021.
5
Expression of the immune checkpoint VISTA in breast cancer.乳腺癌中免疫检查点 VISTA 的表达。
Cancer Immunol Immunother. 2020 Aug;69(8):1437-1446. doi: 10.1007/s00262-020-02554-3. Epub 2020 Apr 7.
6
An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA.一种工程化抗体结合了一个独特的表位,是一种有效的鼠源和人源 VISTA 的抑制剂。
Sci Rep. 2020 Sep 16;10(1):15171. doi: 10.1038/s41598-020-71519-4.
7
Structure and Functional Binding Epitope of V-domain Ig Suppressor of T Cell Activation.V 结构域免疫球蛋白抑制 T 细胞活化蛋白的结构和功能结合表位
Cell Rep. 2019 Sep 3;28(10):2509-2516.e5. doi: 10.1016/j.celrep.2019.07.073.
8
VISTA is an acidic pH-selective ligand for PSGL-1.VISTA 是 PSGL-1 的酸性 pH 选择性配体。
Nature. 2019 Oct;574(7779):565-570. doi: 10.1038/s41586-019-1674-5. Epub 2019 Oct 23.
9
Dual silencing of tumor-intrinsic VISTA and CTLA-4 stimulates T-cell mediated immune responses and inhibits MCF7 breast cancer development.双重沉默肿瘤内在的 VISTA 和 CTLA-4 可刺激 T 细胞介导的免疫反应并抑制 MCF7 乳腺癌的发展。
Gene. 2024 Feb 20;896:148043. doi: 10.1016/j.gene.2023.148043. Epub 2023 Nov 30.
10
VISTA: A promising target for overcoming immune evasion in gynecologic cancers.VISTA:克服妇科癌症免疫逃逸的有前景的靶点。
Int Immunopharmacol. 2024 Sep 10;138:112655. doi: 10.1016/j.intimp.2024.112655. Epub 2024 Jul 9.

引用本文的文献

1
IGSF11-Mediated Immune Modulation: Unlocking a Novel Pathway in Emerging Cancer Immunotherapies.IGSF11介导的免疫调节:开启新兴癌症免疫疗法的新途径。
Cancers (Basel). 2025 Aug 13;17(16):2636. doi: 10.3390/cancers17162636.
2
IgSF11-RAP1 signaling promotes cell migration and invasion of cutaneous melanoma.IgSF11-RAP1信号传导促进皮肤黑色素瘤的细胞迁移和侵袭。
Cell Commun Signal. 2025 Jul 10;23(1):330. doi: 10.1186/s12964-025-02245-5.
3
Negative Immune Checkpoint Inhibitors.阴性免疫检查点抑制剂

本文引用的文献

1
Unraveling the potential of CD8, CD68, and VISTA as diagnostic and prognostic markers in patients with pancreatic ductal adenocarcinoma.解析CD8、CD68和VISTA作为胰腺导管腺癌患者诊断和预后标志物的潜力。
Front Immunol. 2024 Jan 30;15:1283364. doi: 10.3389/fimmu.2024.1283364. eCollection 2024.
2
Corrigendum: A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors.勘误:一种高效抗VISTA抗体KVA12123——一种新型免疫检查点抑制剂及针对低免疫原性肿瘤的有前景的疗法。
Front Immunol. 2024 Jan 23;15:1365240. doi: 10.3389/fimmu.2024.1365240. eCollection 2024.
3
Pharmaceutics. 2025 May 28;17(6):713. doi: 10.3390/pharmaceutics17060713.
4
[IGSF11: A Novel Target for Cancer Immunotherapy].[免疫球蛋白超家族成员11:癌症免疫治疗的新靶点]
Zhongguo Fei Ai Za Zhi. 2025 May 20;28(5):371-378. doi: 10.3779/j.issn.1009-3419.2025.106.14.
5
Comprehensive analysis of SELPLG as a potential immunotherapy target and prognostic biomarker in oncology.对SELPLG作为肿瘤学中潜在免疫治疗靶点和预后生物标志物的综合分析。
Discov Oncol. 2025 Jun 12;16(1):1073. doi: 10.1007/s12672-025-02934-0.
6
Exploring New Frontiers: Alternative Breast Cancer Treatments Through Glycocalyx Research.探索新前沿:通过糖萼研究寻找乳腺癌替代治疗方法
Breast J. 2025 May 22;2025:9952727. doi: 10.1155/tbj/9952727. eCollection 2025.
7
Impact of cannabinoids on cancer outcomes in patients receiving immune checkpoint inhibitor immunotherapy.大麻素对接受免疫检查点抑制剂免疫治疗的患者癌症预后的影响。
Front Immunol. 2025 Mar 5;16:1497829. doi: 10.3389/fimmu.2025.1497829. eCollection 2025.
8
Tumor Microenvironment Drives the Cross-Talk Between Co-Stimulatory and Inhibitory Molecules in Tumor-Infiltrating Lymphocytes: Implications for Optimizing Immunotherapy Outcomes.肿瘤微环境驱动肿瘤浸润淋巴细胞中共刺激分子与抑制分子之间的相互作用:对优化免疫治疗结果的启示。
Int J Mol Sci. 2024 Nov 29;25(23):12848. doi: 10.3390/ijms252312848.
9
VSIG-3/IGSF11 silencing in A2058 melanoma cells simultaneously suppresses melanoma progression and induces anti-tumoral cytokine profile in human T cells: In silico and in vitro study.A2058黑色素瘤细胞中VSIG-3/IGSF11基因沉默同时抑制黑色素瘤进展并诱导人T细胞产生抗肿瘤细胞因子谱:计算机模拟和体外研究
Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr;398(4):3861-3880. doi: 10.1007/s00210-024-03491-z. Epub 2024 Oct 4.
Dual silencing of tumor-intrinsic VISTA and CTLA-4 stimulates T-cell mediated immune responses and inhibits MCF7 breast cancer development.
双重沉默肿瘤内在的 VISTA 和 CTLA-4 可刺激 T 细胞介导的免疫反应并抑制 MCF7 乳腺癌的发展。
Gene. 2024 Feb 20;896:148043. doi: 10.1016/j.gene.2023.148043. Epub 2023 Nov 30.
4
VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy.VISTA及其配体:免疫疗法中新一代有前景的治疗靶点。
Cancer Cell Int. 2023 Nov 7;23(1):265. doi: 10.1186/s12935-023-03116-0.
5
Epidemiology and clinicopathologic features of breast cancer in China and the United States.中国和美国乳腺癌的流行病学及临床病理特征
Transl Cancer Res. 2023 Jul 31;12(7):1826-1835. doi: 10.21037/tcr-22-2799. Epub 2023 Jun 29.
6
Translational Epidemiology: Genetic Ancestry in Breast Cancer: What Is the Role of Genetic Ancestry and Socioeconomic Status in Triple-Negative Breast Cancer?转化流行病学:乳腺癌的遗传背景:遗传背景和社会经济地位在三阴性乳腺癌中的作用是什么?
Adv Surg. 2023 Sep;57(1):1-14. doi: 10.1016/j.yasu.2023.03.001. Epub 2023 May 10.
7
"Diagnostic and Prognostic Biomarkers of Luminal Breast Cancer: Where are We Now?".管腔型乳腺癌的诊断和预后生物标志物:我们目前的进展如何?
Breast Cancer (Dove Med Press). 2023 Jul 28;15:525-540. doi: 10.2147/BCTT.S340741. eCollection 2023.
8
Looking for biomarkers in interferon response pathway to predict response to oncolytic HSV-1 in breast cancer: An ex vivo study.寻找干扰素反应通路中的生物标志物以预测乳腺癌对溶瘤性单纯疱疹病毒1型的反应:一项体外研究。
Cancer Biomark. 2023;38(1):37-47. doi: 10.3233/CBM-230033.
9
Exposome epidemiology for suspect environmental chemical exposures during pregnancy linked to subsequent breast cancer diagnosis.孕期疑似环境化学暴露与随后乳腺癌诊断相关的暴露组流行病学研究。
Environ Int. 2023 Aug;178:108112. doi: 10.1016/j.envint.2023.108112. Epub 2023 Jul 24.
10
Biomarkers in Breast Cancer: An Old Story with a New End.乳腺癌生物标志物:旧故事的新结局。
Genes (Basel). 2023 Jun 28;14(7):1364. doi: 10.3390/genes14071364.